<?xml version="1.0" encoding="UTF-8"?>
<ref id="B16-pathogens-08-00176">
 <label>16.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Roth</surname>
    <given-names>D.</given-names>
   </name>
   <name>
    <surname>Nelson</surname>
    <given-names>D.R.</given-names>
   </name>
   <name>
    <surname>Bruchfeld</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Liapakis</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Silva</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Monsour</surname>
    <given-names>H.</given-names>
    <suffix>Jr.</suffix>
   </name>
   <name>
    <surname>Martin</surname>
    <given-names>P.</given-names>
   </name>
   <name>
    <surname>Pol</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Londoño</surname>
    <given-names>M.C.</given-names>
   </name>
   <name>
    <surname>Hassanein</surname>
    <given-names>T.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Grazoprevir plus elbasvir in treatment naïve and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study)</article-title>
  <source>Lancet</source>
  <year>2015</year>
  <volume>386</volume>
  <fpage>1537</fpage>
  <lpage>1545</lpage>
  <pub-id pub-id-type="doi">10.1016/S0140-6736(15)00349-9</pub-id>
  <pub-id pub-id-type="pmid">26456905</pub-id>
 </element-citation>
</ref>
